MANGALAM vs ORCHPHARMA: Stock Comparison

Mangalam Drugs And Organics Limited vs Orchid Pharma Limited

Live data: 22 July 2026, 2:56 PM IST • Source: NSE and company filings

Orchid Pharma Limited is the larger company by market capitalisation. Orchid Pharma Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mangalam Drugs And Organics Limited and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANGALAM is more favourable on 0 of 11 scored metrics and ORCHPHARMA on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ORCHPHARMA is the larger company
₹5,072 Cr vs ₹43 Cr
EPS
ORCHPHARMA has higher earnings per share
₹4.01 vs ₹-28.05
Revenue Growth (TTM YoY)
ORCHPHARMA has faster revenue growth
-1.5% vs -7.5%
Qtr Sales Growth
ORCHPHARMA has stronger quarterly sales growth
0.05% vs -7.54%
Qtr Profit Growth
ORCHPHARMA has stronger quarterly profit growth
4.26% vs -22,467%
ROE
ORCHPHARMA has a higher ROE
2.12% vs -35.2%
ROCE
ORCHPHARMA has a higher ROCE
2.64% vs -14.3%
Net Margin
ORCHPHARMA has a higher net margin
2.51% vs -19.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMORCHPHARMA
Live Price₹27.08₹999.75
Day Change-0.66%-2.27%
Volume25,35681,527
52-Week High₹95₹1,119.8
52-Week Low₹22.8₹480
Distance from 52W High-71.49%-10.72%

Valuation

MetricMANGALAMORCHPHARMA
Market Cap₹43 Cr₹5,072 Cr
P/E Ratio253.09x
P/B Ratio4.04x
EPS₹-28.05₹4.01
Book Value₹65.12₹253.98
Dividend Yield0%0%

Growth

MetricMANGALAMORCHPHARMA
Revenue Growth (TTM YoY)-7.5%-1.5%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-7.54%0.05%
Qtr Profit Growth-22,467%4.26%

Profitability & Leverage

MetricMANGALAMORCHPHARMA
ROE-35.2%2.12%
ROCE-14.3%2.64%
Net Margin-19.13%2.51%
Operating Margin-6.42%5.07%
Debt to Equity1.02x0.28x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMANGALAMORCHPHARMA
Promoter Holding35.65%69.84%
FII Holding0.11% 0.21 pp0.87% 0.3 pp
DII Holding0%20.25% 0.86 pp
Public Holding64.24% 0.22 pp9.05% 0.55 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mangalam Drugs And Organics Limited and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.